– USA, CA – Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Dr. Kenneth Hillan, an accomplished biotechnology executive, to its Board of Directors.
“We are pleased to welcome Kenneth to the Sangamo Board of Directors,” said CEO, Sandy Macrae. “We believe that Kenneth’s 25 years of clinical development and executive leadership experience, as well as his current focus on the therapeutic applications of DNA sequencing data, will provide great benefit to Sangamo as we continue to advance our growing pipeline of genomic medicines through clinical development.”
Sangamo also today announced that Dr Stephen Dilly will resign from the Board of Directors effective September 30, 2020.
“It has been a great pleasure serving as a Sangamo director for the past decade,” said Dr. Dilly. “With a broad therapeutic pipeline, meaningful collaborations with global biopharmaceutical companies, and a strong balance sheet, Sangamo is well-positioned as a leader in the field of genomic medicine. I’m personally very pleased to welcome Kenneth Hillan to the Board and am excited for the future success of Sangamo.”
About Dr Kenneth Hillan
Since 2019, Dr. Hillan has served as Head of Therapeutics of 23andMe, the consumer genetics and research company, leading dedicated discovery research and therapeutic development team that uses human genetic data to identify and pursue novel therapies for common and rare diseases. Previously, Dr. Hillan held leadership roles in the biotechnology industry. He served at Genentech from 1994 to 2011, where he led the medical and scientific strategies for its Immunology, Tissue Growth and Repair drug portfolio, and held a number of key leadership positions in research and development, including SVP Clinical Development, Inflammation; VP Immunology, Tissue Growth and Repair; VP Development Sciences; and VP Research Operations and Pathology. He also served as Genentech’s SVP and Head of Clinical Development and Product Development Strategy in Asia-Pacific for Roche in Shanghai, China. From 2011 to 2017, he was CEO Achaogen, Inc., where he was also a member of the Board of Directors. He has also served on the Board of Directors of Zymeworks since February 2017 and was a member of the Board of Directors of Relypsa from 2014 until 2016, when it was acquired by Galenica AG.
Dr. Hillan has an M.B. Ch.B. degree from the Faculty of Medicine at the University of Glasgow, U.K. He is a Fellow of the Royal College of Surgeons, and a Fellow of the Royal College of Pathologists. Dr. Hillan has authored dozens of scientific publications and is a named inventor on almost 50 issued patents.
About Sangamo Therapeutics
Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and genome regulation.
For more information: https://www.sangamo.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
